Abstract
DNA topoisomerases are an important family of enzymes that catalyze the induction of topological changes in the DNA molecule. Their ability to modulate the topology of the DNA makes DNA topoisomerases a key player in several vital cell processes such as replication, transcription, chromosome separation and segregation. Consequently, they already represent an important collection of macromolecular targets for some of the established anticancer drugs on the market as well as serve as templates in the development of novel anticancer drugs especially supported by recent structural advances in the field.
The aim of this review is to provide an overview of the recent developments in the field of DNA poisons - a major class of human topoisomerase IIα inhibitors - of which several are already in clinical use. Due to frequently experienced occurrence of serious side effects of these molecules during therapy, especially cardiotoxicity issues, further drug design efforts were initiated already yielding novel promising compounds that have overcome this issue and already entered into clinical studies. Some of the presented and discussed chemical classes include intercalators, non-intercalators and redox-dependent poisons of human topoisomerase IIα. In particular, this review focuses on the currently available structure-based standpoint of molecular design and on the medicinal chemist’s perspective of this field of anticancer drug design.
Keywords: DNA topoisomerase IIα, DNA poisons, intercalators, non-intercalators, redox-dependent poisons, inhibitors, anticancer agents, medicinal chemistry, drug design, cardiotoxicity
Current Pharmaceutical Design
Title:Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Volume: 19 Issue: 13
Author(s): Barbara Pogorelcnik, Andrej Perdih and Tom Solmajer
Affiliation:
Keywords: DNA topoisomerase IIα, DNA poisons, intercalators, non-intercalators, redox-dependent poisons, inhibitors, anticancer agents, medicinal chemistry, drug design, cardiotoxicity
Abstract: DNA topoisomerases are an important family of enzymes that catalyze the induction of topological changes in the DNA molecule. Their ability to modulate the topology of the DNA makes DNA topoisomerases a key player in several vital cell processes such as replication, transcription, chromosome separation and segregation. Consequently, they already represent an important collection of macromolecular targets for some of the established anticancer drugs on the market as well as serve as templates in the development of novel anticancer drugs especially supported by recent structural advances in the field.
The aim of this review is to provide an overview of the recent developments in the field of DNA poisons - a major class of human topoisomerase IIα inhibitors - of which several are already in clinical use. Due to frequently experienced occurrence of serious side effects of these molecules during therapy, especially cardiotoxicity issues, further drug design efforts were initiated already yielding novel promising compounds that have overcome this issue and already entered into clinical studies. Some of the presented and discussed chemical classes include intercalators, non-intercalators and redox-dependent poisons of human topoisomerase IIα. In particular, this review focuses on the currently available structure-based standpoint of molecular design and on the medicinal chemist’s perspective of this field of anticancer drug design.
Export Options
About this article
Cite this article as:
Pogorelcnik Barbara, Perdih Andrej and Solmajer Tom, Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130016
DOI https://dx.doi.org/10.2174/1381612811319130016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies
Current Cancer Drug Targets Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters Synthetic Peptides in the Diagnosis of HIV Infection
Current Protein & Peptide Science Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Mini-Reviews in Medicinal Chemistry FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents
Current Medicinal Chemistry Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Phytochemicals, Medicinal and Food Applications of Shatavari (Asparagus racemosus): An Updated Review
The Natural Products Journal Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry